Project Grant R01DK145514
Award Date 7/30/26
Completion Date 5/31/31
Dollars Obligated $562K
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Boston, MA 02114, USA
Similar Awards
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (Massachusetts General Hospital) $749,727 on August 5, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate parathyroid hormone receptor signaling in podocyte injury and chronic kidney disease progression. The funded research will define the pathological role of PTH/PTH1R signaling in podocyte injury, elucidate underlying...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $251,626 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to conduct basic research on c-kit receptor signaling in kidney collecting duct function. The research investigates the role of c-kit receptor signaling in modulating collecting duct epithelial cell composition and function. The project uses c-kit "sash" mice...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $197,320 on April 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support career development and investigator-initiated research in glycemic monitoring and management. The award funds research by Dr. Mengyao Tang, a board-certified nephrologist at Massachusetts General Hospital, to...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Massachusetts General Hospital $622,959 under Project Grant R01DK146964 on April 15, 2026, to investigate the role of glycerol-3-phosphate acyltransferase 2 (GPAT2) in regulating mineral metabolism dysfunction in chronic kidney disease. The research aims to elucidate a kidney-driven mechanism in which glycerol-3-phosphate released from injured renal tissue stimulates production of fibroblast growth factor 23 (FGF23),...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The General Hospital Corporation (doing business as Massachusetts General Hospital) $158,696 on January 17, 2027, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to support research investigating the role of intestinal fibrosis in Hirschsprung disease. The research characterizes cellular and molecular features of the aganglionic bowel segment and tests anti-fibrotic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded The Children's Hospital Corporation (Boston Children's Hospital) $133,500 on July 6, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate integrin αVβ6-mediated activation of latent TGF-β2 in kidney fibrosis. The research will test the hypothesis that integrin αVβ6-mediated TGF-β2 activation drives renal fibrosis and represents a potential therapeutic...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Tufts Medical Center Parent, Inc. (doing business as Tufts Medical Center) $133,875 on September 1, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The project grant funds an evaluation of how estimated glomerular filtration rate (eGFR) decline influences clinical practice patterns of medication withdrawal in heart failure patients. The research addresses a significant...
- Federal Grant Award Summary Massachusetts General Hospital received a $133,328 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 20, 2025 through September 19, 2026. The award funds research investigating the distinct roles of PPM1D and TP53 mutations in hematopoietic stem cells and clonal hematopoiesis, with emphasis on...
- The National Institute of Diabetes and Digestive and Kidney Diseases awarded Boston Medical Center Corporation $152,777 on August 13, 2026, under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to investigate the role of uremic toxins as mediators of cardiovascular-kidney-metabolic syndrome and peripheral artery disease in chronic kidney disease patients. The research examines tryptophan-derived uremic toxins, particularly kynurenine and its metabolites, as...
- Federal Project Grant Award Summary Brigham & Women's Hospital Inc. received a $2.47 million Project Grant from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), effective September 1, 2025, through August 31, 2029. This award supports the development of a novel, kidney-draining lymph node (KLN)-targeted nanotherapeutic to treat crescentic glomerulonephritis (CGN), a...